AKESF Quote, Financials, Valuation and Earnings

CASI Pharmaceuticals, Inc. has a net margin of -- compared to Akeso, Inc.'s net margin of -353.92%. Akeso, Inc.'s return on equity of -15.02% beat CASI Pharmaceuticals, Inc.'s return on equity of -70405.41%.

Akeso, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand CASI Pharmaceuticals, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 316.62%. Given that CASI Pharmaceuticals, Inc. has higher upside potential than Akeso, Inc., analysts believe CASI Pharmaceuticals, Inc. is more attractive than Akeso, Inc..

Akeso, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CASI Pharmaceuticals, Inc. has a beta of 0.853, suggesting its less volatile than the S&P 500 by 14.657%.

Akeso, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akeso, Inc. pays -- of its earnings as a dividend. CASI Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Akeso, Inc. quarterly revenues are --, which are smaller than CASI Pharmaceuticals, Inc. quarterly revenues of $3.1M. Akeso, Inc.'s net income of -- is lower than CASI Pharmaceuticals, Inc.'s net income of -$10.9M. Notably, Akeso, Inc.'s price-to-earnings ratio is 18.19x while CASI Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akeso, Inc. is 39.42x versus 0.56x for CASI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

China Pharma Holdings, Inc. has a net margin of -- compared to Akeso, Inc.'s net margin of -86.16%. Akeso, Inc.'s return on equity of -15.02% beat China Pharma Holdings, Inc.'s return on equity of -43.41%.

Akeso, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand China Pharma Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Akeso, Inc. has higher upside potential than China Pharma Holdings, Inc., analysts believe Akeso, Inc. is more attractive than China Pharma Holdings, Inc..

Akeso, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison China Pharma Holdings, Inc. has a beta of 1.028, suggesting its more volatile than the S&P 500 by 2.826%.

Akeso, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akeso, Inc. pays -- of its earnings as a dividend. China Pharma Holdings, Inc. pays out -- of its earnings as a dividend.

Akeso, Inc. quarterly revenues are --, which are smaller than China Pharma Holdings, Inc. quarterly revenues of $756.2K. Akeso, Inc.'s net income of -- is lower than China Pharma Holdings, Inc.'s net income of -$651.5K. Notably, Akeso, Inc.'s price-to-earnings ratio is 18.19x while China Pharma Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akeso, Inc. is 39.42x versus 1.37x for China Pharma Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sinovac Biotech Ltd. has a net margin of -- compared to Akeso, Inc.'s net margin of --. Akeso, Inc.'s return on equity of -15.02% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.

Akeso, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Akeso, Inc. has higher upside potential than Sinovac Biotech Ltd., analysts believe Akeso, Inc. is more attractive than Sinovac Biotech Ltd..

Akeso, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.723, suggesting its less volatile than the S&P 500 by 27.741%.

Akeso, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. Akeso, Inc. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.

Akeso, Inc. quarterly revenues are --, which are smaller than Sinovac Biotech Ltd. quarterly revenues of --. Akeso, Inc.'s net income of -- is lower than Sinovac Biotech Ltd.'s net income of --. Notably, Akeso, Inc.'s price-to-earnings ratio is 18.19x while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akeso, Inc. is 39.42x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Zai Lab Ltd. has a net margin of -- compared to Akeso, Inc.'s net margin of -30.98%. Akeso, Inc.'s return on equity of -15.02% beat Zai Lab Ltd.'s return on equity of -26.7%.

Akeso, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab Ltd. has an analysts' consensus of $49.49 which suggests that it could grow by 153.79%. Given that Zai Lab Ltd. has higher upside potential than Akeso, Inc., analysts believe Zai Lab Ltd. is more attractive than Akeso, Inc..

Akeso, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.872, suggesting its less volatile than the S&P 500 by 12.778%.

Akeso, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akeso, Inc. pays -- of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.

Akeso, Inc. quarterly revenues are --, which are smaller than Zai Lab Ltd. quarterly revenues of $116.2M. Akeso, Inc.'s net income of -- is lower than Zai Lab Ltd.'s net income of -$36M. Notably, Akeso, Inc.'s price-to-earnings ratio is 18.19x while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akeso, Inc. is 39.42x versus 4.74x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.